Chronic mast cell leukemia: A novel leukemia-variant with distinct morphological and clinical features

Leukemia Research

Volumn 39, Issue 1, 2015, Pages 1-5

  Valent, Peter ^a   Sotlar, Karl ^b   Sperr, Wolfgang R ^a   Reiter, Andreas ^c   Arock, Michel ^d   Horny, Hans Peter ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Ecole Normale Superieure de Cachan   (France)

Author keywords

Chronic mast cell leukemia; KIT mutation; Mast cells; Mastocytosis

Indexed keywords

CD2 ANTIGEN; CD30 ANTIGEN; CD52 ANTIGEN; CLADRIBINE; HYDROXYUREA; IMATINIB; INTERLEUKIN 2 RECEPTOR ALPHA; KI 67 ANTIGEN; MIDOSTAURIN; MOLECULAR MARKER; PREDNISOLONE; TRYPTASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; BONE MARROW BIOPSY; CELL SURFACE; CHRONIC LEUKEMIA; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAST CELL LEUKEMIA; PHENOTYPE; REVIEW; TREATMENT RESPONSE; ACUTE DISEASE; CHRONIC DISEASE; CLASSIFICATION; COMPARATIVE STUDY; DRUG RESISTANCE; LEUKEMIA, MAST-CELL; METABOLISM; PATHOLOGY;

ACUTE DISEASE; CHRONIC DISEASE; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MAST-CELL;

EID: 84920459044     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.09.010     Document Type: Review

References (45)

1. Valent P., Horny H.P., Escribano L., Longley B.J., Li C.Y., Schwartz L.B., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001, 25:603-625.
2. Valent P., Horny H.-P., Li C.Y., Longley J.B., Metcalfe D.D., Parwaresch R.M., et al. Mastocytosis (mast cell disease). World Health Organization (WHO) classification of tumours. Pathology & genetics. Tumours of haematopoietic and lymphoid tissues 2001, 291-302. IARC Press Lyon, France. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (Eds.).
3. Horny H.P., Metcalfe D.D., Bennett J.M., Bain B.J., Akin C., Escribano L., et al. Mastocytosis (mast cell disease). World Health Organization (WHO) classification of tumours. Pathology & genetics. Tumours of haematopoietic and lymphoid tissues 2008, 54-63. IARC Press, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman (Eds.).
4. Valent P., Akin C., Sperr W.R., Horny H.P., Metcalfe D.D. Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematol Oncol Clin North Am 2003, 17:1227-1241.
5. Travis W.D., Li C.Y., Hoagland H.C., Travis L.B., Banks P.M. Mast cell leukemia: report of a case and review of the literature. Mayo Clin Proc 1986, 61:957-966.
6. Sperr W.R., Escribano L., Jordan J.H., Schernthaner G.H., Kundi M., Horny H.P., et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res 2001, 25:529-536.
7. Lim K.H., Tefferi A., Lasho T.L., Finke C., Patnaik M., Butterfield J.H., et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009, 113:5727-5736.
8. Pardanani A., Lim K.H., Lasho T.L., Finke C., McClure R.F., Li C.Y., Tefferi A. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 2009, 114(18):3769-3772.
9. Dalton R., Chan L., Batten E., Eridani S. Mast cell leukaemia: evidence for bone marrow origin of the pathologic clone. Br J Haematol 1986, 64(2):397-406.
10. Baghestanian M., Bankl H.C., Sillaber C., Beil W.J., Radaszkiewicz T., Füreder W., et al. A case of malignant mastocytosis with circulating mast cell precursors: biologic and phenotypic characterization of the malignant clone. Leukemia 1996, 10(1):159-166.
11. Teodosio C., García-Montero A.C., Jara-Acevedo M., Sánchez-Muñoz L., Alvarez-Twose I., Núñez R., et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol 2010, 125:719-726.
12. Pagano L., Valentini C.G., Caira M., Rondoni M., Van Lint M.T., Candoni A., et al. Advanced mast cell disease: an Italian hematological multicenter experience. Int J Hematol 2008, 88:483-488.
13. Chan E.C., Bai Y., Kirshenbaum A.S., Fischer E.R., Simakova O., Bandara G., et al. Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype. J Allergy Clin Immunol 2014, 134:178-187.
14. Valent P., Sotlar K., Sperr W.R., Escribano L., Yavuz S., Reiter A., et al. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol 2014, 25:1691-1700.
15. Horny H.P., Parwaresch M.R., Lennert K. Bone marrow findings in systemic mastocytosis. Hum Pathol 1985, 16:808-814.
16. Horny H.P., Sillaber C., Menke D., Kaiserling E., Wehrmann M., Stehberger B., et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998, 22:1132-1140.
17. Horny H.P., Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001, 25:543-551.
18. Krokowski M., Sotlar K., Krauth M.T., Födinger M., Valent P., Horny H.P. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia. Am J Clin Pathol 2005, 124:560-568.
19. Sotlar K., Horny H.P., Simonitsch I., Krokowski M., Aichberger K.J., Mayerhofer M., et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004, 28:1319-1325.
20. Sotlar K., Cerny-Reiterer S., Petat-Dutter K., Hessel H., Berezowska S., Müllauer L., et al. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol 2011, 24:585-595.
21. Hoermann G., Blatt K., Greiner G., Putz E.M., Berger A., Herrmann H., et al. CD52 is a molecular target in advanced systemic mastocytosis. FASEB J 2014, 28:3540-3551.
22. Valent P., Blatt K., Eisenwort G., Herrmann H., Cerny-Reiterer S., Thalhammer R., et al. FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H. Leuk Res Rep 2013, 3:8-13.
23. Valent P., Berger J., Cerny-Reiterer S., Eisenwort G., Peter B., Hoermann G., et al. A case of chronic mast cell leukemia: an extremely rare entity defined by mast cell maturation and absence of severe organ damage. Ann Hematol 2014, (in press).
24. Escribano L., Orfao A., Díaz-Agustin B., Villarrubia J., Cerveró C., López A., et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998, 91:2731-2736.
25. Escribano L., Díaz-Agustín B., Bellas C., Navalón R., Nuñez R., Sperr W.R.. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res 2001, 25:563-570.
26. Escribano L., Orfao A., Villarrubia J., Martín F., Madruga J.I., Cuevas M., et al. Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia. Cytometry 1997, 30:98-102.
27. Teodosio C., García-Montero A.C., Jara-Acevedo M., Sánchez-Muñoz L., Pedreira C.E., Álvarez-Twose I., et al. Gene expression profile of highly purified bone marrow mast cells in systemic mastocytosis. J Allergy Clin Immunol 2013, 131:1213-1224.
28. Schernthaner G.H., Jordan J.H., Ghannadan M., Agis H., Bevec D., Nuñez R., et al. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood 2001, 98:3784-3792.
29. Morgado J.M., Perbellini O., Johnson R.C., Teodósio C., Matito A., Álvarez-Twose I., et al. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. Histopathology 2013, 63:780-787.
30. Nagata H., Worobec A.S., Oh C.K., Chowdhury B.A., Tannenbaum S., Suzuki Y., et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995, 92:10560-10564.
31. Fritsche-Polanz R., Jordan J.H., Feix A., Sperr W.R., Sunder-Plassmann G., Valent P., et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 2001, 113:357-364.
32. Bibi S., Langenfeld F., Jeanningros S., Brenet F., Soucie E., Hermine O., et al. Molecular defects in mastocytosis: KIT and beyond KIT. Immunol Allergy Clin North Am 2014, 34:239-262.
33. Mital A., Piskorz A., Lewandowski K., Wasag B., Limon J., Hellmann A. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol 2011, 86:531-535.
34. Joris M., Georgin-Lavialle S., Chandesris M.O., Lhermitte L., Claisse J.F., Canioni D., et al. Mast cell leukaemia: c-KIT mutations are not always positive. Case Rep Hematol 2012, 2012:517546.
35. Georgin-Lavialle S., Lhermitte L., Suarez F., Yang Y., Letard S., Hanssens K., et al. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. Eur J Haematol 2012, 89:47-52.
36. Arock M., Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol 2010, 3:497-516.
37. Bodemer C., Hermine O., Palmérini F., Yang Y., Grandpeix-Guyodo C., Leventhal P.S., et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010, 130:804-815.
38. Tefferi A., Levine R.L., Lim K.H., Abdel-Wahab O., Lasho T.L., Patel J., et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009, 23:900-904.
39. Wilson T.M., Maric I., Simakova O., Bai Y., Chan E.C., Olivares N., et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica 2011, 96:459-463.
40. Schwaab J., Schnittger S., Sotlar K., Walz C., Fabarius A., Pfirrmann M., et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013, 122:2460-2466.
41. Sperr W.R., Horny H.P., Lechner K., Valent P. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma 2000, 37:473-486.
42. Valent P., Akin C., Sperr W.R., Escribano L., Arock M., Horny H.P., Bennett J.M., Metcalfe D.D. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003, 27:635-641.
43. Gotlib J., Berubé C., Growney J.D., Chen C.C., George T.I., Williams C., et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005, 106:2865-2870.
44. Georgin-Lavialle S., Lhermitte L., Dubreuil P., Chandesris M.O., Hermine O., Damaj G. Mast cell leukemia. Blood 2013, 121:1285-1295.
45. Ustun C., Reiter A., Scott B.L., Nakamura R., Damaj G., Kreil S., et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol 2014, 32:3264-3274.